LAVAL, QC, Aug. 2 /CNW Telbec/ - Neptune Technologies &
Bioressources Inc., (TSX.V: NTB), "Neptune" is pleased to announce
significantly positive results after the completion of a population-based
risk-benefit and a health-economics analysis study for Neptune Krill Oil
(NKO(TM)) in the management of dyslipidemia. The health-economic analysis was
based on the 2003 hyperlipidemia study, a randomized, placebo controlled,
clinical trial in which 90 patients who were either newly diagnosed, never
treated for high cholesterol or using statins for at least 6 months, without
effect, at the time of study initiation and concurrently with the study
The analysis was conducted between January and August 2007 by a team of
renowned researchers: Dr. Keith Worsley MSc., PhD, FRSC and recipient of the
Gold Medal, Statistical Society of Canada, affiliated with McGill University
of Montreal; Dr. Shahin Jaffer, MD, FRCPC Head, Department of Medicine, Delta
Hospital, University of British Columbia; and Dr. A. Shekhar Pandey, B.Sc.,
MD, FRCPC, ABIM, CBNC, Adult Invasive, Non-invasive, & Preventive
Cardiologist, Cambridge Cardiac Care Centre, Cambridge, Ontario.
The economic model for the analysis was based on the 10-year risk for
cardiovascular disease as estimated by the Framingham model. According to this
model, an individual's 10-year risk for a cardiovascular event is a function
of age, gender, systolic blood pressure, TC, HDL-C, smoking status and
presence of left ventricular hypertrophy as detected by an electrocardiogram.
The model is based on a logistic regression analysis derived on a cohort of
over 5,000 patients that have been followed for 40 years or more.
The Framingham model has been shown to be a valid predictor of
cardiovascular risk. Therefore, changes in the Framingham-derived risk
estimates are considered to represent the change in the individual patient
cardiovascular risk that are sensitive to change induced by preventive
interventions. The logistic regression parameters are used to estimate the
patient's 10-year risk for having a cardiovascular event.
The results of the study demonstrate the following:
a. Patients treated with NKO had significantly reduced risk for
cardiovascular events over the next 10 years, by 52%.
b. Patients treated with NKO had a significantly higher chance (-52.3%)
to prevent cardiovascular events over the next 10 years when compared
to those treated with Fish Oil (-8.9%) or the statin resistant
patients treated with low dose statin (83.6%) (P (less than) 0.001).
c. NKO monotherapy as well as NKO co-administered with a low dose statin
was significantly more cost-effective than all other interventions
studied for all types of cardiovascular events aggregated.
d. From a cost-benefit perspective NKO remains the most favorable
treatment alternative for angina, congestive heart failure, stroke,
myocardial infarction, Percutaneous Transluminal Coronary Angioplasty
(PTCA), fatal myocardial infarction and coronary artery bypass graft
surgery (CABG); NKO has a negative cost-benefit indicating that the
cost of acquisition is less than the benefits derived from the
e. With respect to death and cardiac arrests that are rare events, the
cost-benefit ratio is positive indicating the acquisition cost is
higher than the benefits derived. However, NKO remained the least
expensive alternative for these rare events.
f. Under the 90 day and 10 year treatment assumption, NKO maintained a
favorable cost-benefit profile with cost savings for angina, PTCA and
The authors conclude that "The results of this analysis have shown that
NKO as monotherapy or given in combination with a statin is efficient and
cost-effective in the management of dyslipidemia". In addition the authors
concluded that "The results have important implications for the management of
the growing population of patients with dyslipidemia, who require safe and
effective treatment and who may not be responsive, nor tolerant, nor
appropriate candidates for treatment with a statin alone".
"Benefit, risk and economic assessments are now the pivotal points not
only for government approval of medicine for treatment of diseases that
require long-term care but are also considered important factors for the
pharmaceutical industry decision makers before taking over the development of
a new drug" stated Dr. Tina Sampalis M.D., Ph.D., Vice-President of R&D and
Business Development of Neptune. "I am extremely proud that we have now
successfully completed this study that was an important achievement for the
pharmaceutical development of NKO. With the results of this analysis we have
now provided valuable evidence that NKO reduces cardiovascular risk while
remaining cost effective and even cost minimizing over many years of use."
About Neptune Technologies & Bioressources Inc.
Neptune Technologies & Bioressources Inc. develops proprietary and potent
health ingredients from underexploited marine biomasses, such as krill, with
its patented extraction process (Neptune OceanExtract(TM)). Using its
proprietary process, Neptune Technologies & Bioressources Inc. is
strategically positioning itself in the nutraceutical and pharmaceutical
health and wellness market.
The Company develops and markets new formulas and new products for
specific applications in high growth markets such the nutraceutical,
cosmeceutical, biopharmaceutical and nutrigenomics markets, the next wave in
nutritional research. Through strategic alliances and partnerships, as well as
through clinical studies, the Company continues to demonstrate the immense
beneficial effects of these products.
The TSX.V has not reviewed and does not accept responsibility for the
adequacy and accuracy of this news release.
Statements in this press release that are not statements of historical or
current fact constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties, and other unknown
factors that could cause the actual results of the Company to be materially
different from the historical results, from any future results expressed, or
implied by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are urged to
consider statements labeled with the terms "believes," "belief," "expects,"
"intends," "anticipates," "will," or "plans" to be uncertain and
forward-looking. The forward-looking statements contained herein are also
subject generally to other risks and uncertainties that are described from
time to time in the Company's reports and registration statements filed with
the Securities and Exchange Commission.
%SEDAR: 00015144E %CIK: 0001401395
For further information:
For further information: US Contact: John Tsemberides, ROI Group LLC,
(212) 495-0743, firstname.lastname@example.org; Canada Contact: Grant Howard, The Howard
Group, Toll free: (888) 221-0915, email@example.com,
www.howardgroupinc.com; Company Contact: André Godin, V.P Administration and
Finance, Neptune Technologies & Bioressources Inc.,
firstname.lastname@example.org, www.neptunebiotech.com; SOURCE: Neptune
Technologies & Bioressources Inc.